PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD

PHASE3CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

October 28, 2022

Study Completion Date

December 16, 2022

Conditions
Anemia of Chronic Kidney Disease
Interventions
DRUG

Ferric citrate

Ferric citrate will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.

DRUG

Placebo

Matching placebo will be provided as a 1g tablet. All intervention doses will be based on hemoglobin levels.

Trial Locations (12)

10002

Department of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital, Taipei

11217

Division of Nephrology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei

20401

Division of Nephrology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, Keelung

22060

Division of Nephrology, Department of Internal Medicine, Far East Memorial Hospital, New Taipei City

23561

Division of Nephrology, Department of Internal Medicine, Taipei Medical University-Shuang Ho Hospital, Taipei County

40433

Division of Nephrology, Department of Internal Medicine, China Medical University Hospital, Taichung

80756

Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

83301

Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung City

Unknown

National Cheng Kung University Hospital, Tainan City

Taipei Medical University Hospital, Taipei

Taipei Municipal Wanfang Hospital, Taipei

Chang Gung Memorial Hospital, Linkou, Taoyuan District

Sponsors
All Listed Sponsors
lead

Panion & BF Biotech Inc.

INDUSTRY